Peptides DB
Research-centric peptide and protocol reference hub

TB-500 (Thymosin Beta-4 Fragment) record · updated 20h ago

Healing & recoveryMuscle & body compGrade B · human evidenceResearch use only
All 5 studiesJump to the evidenceCompare
What is TB-500 (Thymosin Beta-4 Fragment) used for?

TB-500, a synthetic derivative of thymosin beta-4, is a peptide that has garnered attention for its potential role in tissue repair and regeneration. Research into TB-500 is ongoing, particularly regarding its applications in equine medicine and its implications in doping control.

How it works: Actin-sequestering peptide; promotes cell migration & angiogenesis

Primarily researched for · Healing & recoveryRoute · Subcutaneous injection (research use)

Development stage

where TB-500 (Thymosin Beta-4 Fragment) sits between preclinical work and regulatory approval
  1. 1Current
    Preclinical
    Animal / in-vitro work
  2. 2Not reached
    Phase 1
    Safety in humans
  3. 3Not reached
    Phase 2
    Efficacy signal
  4. 4Not reached
    Phase 3
    Confirmatory trials
  5. 5Not reached
    Approved
    Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus and 7 registered trials. It describes the research record, not a recommendation.

Identity
NameTB-500 (Thymosin Beta-4 Fragment)
Chain length7 amino acids
Molecular weight889 Da
FormulaC38H68N10O14
Structure typePeptide
ClassHealing
Research levelWell Studied
Discovered byCurated master list · 2025

Mass and formula from PubChem CID 62707662. The chain length is only shown where the residues account for that mass, so a figure here has been checked against it rather than taken on trust.

Pharmacology
MechanismActin-sequestering peptide; promotes cell migration & angiogenesis
RouteSubcutaneous injection (research use)
Half-life
Time to peak
Duration
Extraction confidence0.50
Effect profile · 0–5
These seven scores are generated by the Librarian — an autonomous agent running GPT-4o over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Aug 11, 2026. How this works →
Research stats
Total studies5
Human / animal / cellular1 / 1 / 1
Highest trial phasePreclinical
Years covered2012–2026
Latest study20d ago
Publication history
20122026
Research funding
no NIH grants found
Safety signals
FAERS reportsnone recorded
Serious AEs in animal work
Community reports
Positive Neutral Negative
Records

Study register

5 rowsOpen in the library →

What people are saying

anecdotal · not evidence

Unverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching TB-500 (Thymosin Beta-4 Fragment) will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.

Community collection has not run yet, so this is an empty shelf rather than a quiet one — nothing has been read, and no conclusion about how much TB-500 (Thymosin Beta-4 Fragment) is discussed should be drawn from it.